A Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin Versus Low-Molecular Weight Heparin

Overview

Journal Clin Pharmacol

Publisher Dove Medical Press

Specialty Pharmacology

Date 2024 Dec 16

PMID 39677557

Authors

Lina Naseralallah

Dima Nasrallah

Somaya Koraysh

Shimaa Aboelbaha

Tarteel Ali Hussain

Affiliations

Soon will be listed here.

Abstract

Background: Heparin and its derivates, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), are among the most commonly used anticoagulants. Nonetheless, their use has been associated with hyperkalemia.

Objective: To determine and compare the incidence, magnitude, and potential risk factors of hyperkalemia in patients receiving UFH versus LMWH in a real-world clinical setting.

Methods: A retrospective observational study was conducted involving all adult hospitalized patients who received UFH, dalteparin or enoxaparin. Electronic medical records were reviewed over a 12-month period, collecting data on demographic, laboratory, comorbidity, and medication-related variables. Data were analyzed using multivariate logistic regression.

Results: A total of 929 patients met the eligibility criteria, with a mean age of over 40 years across all groups. Of these, 56.3%, 17.2%, and 15.7% experienced hyperkalemia with UFH, dalteparin and enoxaparin, respectively. The incidence of hyperkalemia was significantly higher with UFH compared to enoxaparin and dalteparin (p<0.001). Diabetes mellitus was associated with a higher incidence of hyperkalemia (OR 1.79, 95% CI 1.241-2.581, p=0.002), as was the concomitant use of co-trimoxazole (OR 2.244, 95% CI 1.137-4.426, p=0.02). Whilst chronic kidney disease and the use of two or more hyperkalemia-inducing agents were not statistically significant, they were retained in the model as they were associated with more than a 10% increase in the odds of hyperkalemia.

Conclusion: Heparin (UFH, LMWH) administration was associated with a risk of hyperkalemia particularly in patients with diabetes mellitus and those concurrently receiving co-trimoxazole.

References

Coste A, Wong A, Bokern M, Bate A, Douglas I . Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review. Pharmacoepidemiol Drug Saf. 2022; 32(1):28-43. PMC: 10092128. DOI: 10.1002/pds.5548. View

Montford J, Linas S . How Dangerous Is Hyperkalemia?. J Am Soc Nephrol. 2017; 28(11):3155-3165. PMC: 5661285. DOI: 10.1681/ASN.2016121344. View

Melzer N, Bramlage P, Michaelis H . Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial. BMC Res Notes. 2014; 7:880. PMC: 4307893. DOI: 10.1186/1756-0500-7-880. View

Kovacs J, Talib S, Khashan A, Garsondiya B, Carson M . A 77-Year-Old Man with Heparin-Induced Aldosterone Suppression Causing Hyperkalemia. Am J Case Rep. 2022; 23:e937017. PMC: 9319301. DOI: 10.12659/AJCR.937017. View

. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972; 498:1-25. View

Potti A, Tadros S, Koka V, Hanekom D, Fraiman G, Danielson B . Effect of low-molecular-weight heparin on potassium homeostasis. Pathophysiol Haemost Thromb. 2002; 32(3):107-10. DOI: 10.1159/000065208. View

Amir O, Hassan Y, Sarriff A, Awaisu A, Aziz N, Ismail O . Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharm World Sci. 2009; 31(3):387-93. DOI: 10.1007/s11096-009-9288-x. View

Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M . Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol. 2003; 59(5-6):373-7. DOI: 10.1007/s00228-003-0626-y. View

Orlando M, Dillon M, ODell M . Heparin-induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil. 2000; 79(1):93-6. DOI: 10.1097/00002060-200001000-00019. View

10.

Perazella M . Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf. 2000; 22(3):227-36. DOI: 10.2165/00002018-200022030-00006. View

11.

Oduah E, Linhardt R, Sharfstein S . Heparin: Past, Present, and Future. Pharmaceuticals (Basel). 2016; 9(3). PMC: 5039491. DOI: 10.3390/ph9030038. View

12.

Jahromi S, Mahmoodi M, Behroozi F, Roozbeh J, Emamghoreishi F . Effect of switching unfractionated heparin to low-molecular-weight heparin on serum potassium in hemodialysis patients. Iran J Kidney Dis. 2014; 8(6):475-80. View

13.

Hottelart C, Achard J, Moriniere P, Zoghbi F, Dieval J, Fournier A . Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs. 1998; 22(7):614-7. DOI: 10.1046/j.1525-1594.1998.06204.x. View

14.

Yamamoto H, Kayanuma G, Nagashima T, Toda C, Nagayasu K, Kaneko S . Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data. Drug Saf. 2023; 46(4):371-389. PMC: 10113351. DOI: 10.1007/s40264-023-01278-4. View

15.

Parameswaran Nair N, Chalmers L, Peterson G, Bereznicki B, Castelino R, Bereznicki L . Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool. Clin Interv Aging. 2016; 11:497-505. PMC: 4859526. DOI: 10.2147/CIA.S99097. View

16.

Amdetsion G, Gudeta A, Lumley G, Sagoo H, Aliledhin E . Heparin-induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review. EJHaem. 2023; 4(4):1110-1116. PMC: 10660614. DOI: 10.1002/jha2.801. View

17.

Edes T . Heparin-induced hyperkalemia. Postgrad Med. 1990; 87(4):104-6. DOI: 10.1080/00325481.1990.11704598. View

18.

Lu Z . Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf. 2011; 1:35-45. PMC: 3108683. DOI: 10.2147/dhps.s7180. View

19.

Oster J, Singer I, Fishman L . Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995; 98(6):575-86. DOI: 10.1016/s0002-9343(99)80017-5. View

20.

Norman N, Sneed A, Brown C, Ellis C, Minard G, Brown R . Heparin-induced hyponatremia. Ann Pharmacother. 2004; 38(3):404-7. DOI: 10.1345/aph.1C442. View